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Abstract Scoliosis—structural lateral curvature of the
spine—affects around four children per 1,000. The MAGEC
system comprises a magnetically distractible spinal rod
implant and an external remote controller, which lengthens the
rod; this system avoids repeated surgical lengthening. Rod
implants brace the spine internally and are lengthened as the
child grows, preventing worsening of scoliosis and delaying
the need for spinal fusion. The Medical Technologies Advi-
sory Committee at the National Institute for Health and Care
Excellence (NICE) selected the MAGEC system for evalua-
tion in a NICE medical technologies guidance. Six studies
were identified by the sponsor (Ellipse Technologies Inc.) as
being relevant to the decision problem. Meta-analysis was
used to compare the clinical evidence results with those of one
conventional growth rod study, and equal efficacy of the two
devices was concluded. The key weakness was selection of a
single comparator study. The External Assessment Centre
(EAC) identified 16 conventional growth rod studies and
undertook meta-analyses of relevant outcomes. Its critique
highlighted limitations around study heterogeneity and vari-
ations in baseline characteristics and follow-up duration,
precluding the ability to draw firm conclusions. The sponsor
constructed a de novo costing model showing that MAGEC
rods generated cost savings of £9,946 per patient after 6 years,
compared with conventional rods. The EAC critiqued and
updated the model structure and inputs, calculating robust cost
savings of £12,077 per patient with MAGEC rods compared
with conventional rods over 6 years. The year of valuation
was 2012. NICE issued a positive recommendation as sup-
ported by the evidence (Medical Technologies Guidance 18).
Key Points for Decision Makers
The case for adopting the MAGEC system for spinal
lengthening in children with scoliosis is supported by
the evidence. Use of the MAGEC system would
avoid repeated surgical procedures for growth rod
lengthening. This could reduce complications and
could have other physical and psychological benefits
for affected children and their families.
The MAGEC system is indicated for use in children aged
2 years and over with scoliosis who need surgery to
correct their spinal curvature—for example, when con-
servative methods such as bracing or casting have failed.
Findings from cost modelling estimate that use of the
MAGEC system is cost saving, compared with
conventional growth rods, from about 3 years after
the first insertion. The estimated cost saving per
child after 6 years is around £12,077. The cost
savings remained robust in sensitivity analyses.
Further savings could be made by avoiding the need
for spinal cord monitoring, which is sometimes used
during conventional growth rod lengthening but is
not needed for lengthening of MAGEC growth rods.
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1 Introduction
The National Institute of Health and Care Excellence
(NICE) produces evidence-based medical technologies
guidance with the overall aims of evaluating and, where
appropriate, encouraging adoption of novel and innovative
medical devices and diagnostics within the National Health
Service (NHS) in England. Manufacturers or distributors of
potentially eligible technologies submit notifications
regarding their products to NICE’s Medical Technologies
Evaluation Programme (MTEP). Technologies are selected
for evaluation by the programme if they have the potential
to offer significant clinical benefits to patients and the NHS
or to reduce costs, compared with current standard practice.
Guidance is issued after the clinical and cost evidence
submitted by the sponsor is assessed independently by an
External Assessment Centre (EAC) and after a public
consultation period. Devices and diagnostic tools with
more complex value propositions can be routed for eval-
uation through other NICE programmes, such as the
Diagnostics Assessment Programme. Campbell and
Campbell [1] have described the methods of MTEP in
more detail.
The MAGEC system comprises a magnetically dis-
tractible spinal rod implant and an external remote con-
troller, which is used to distract (lengthen) the implant. The
device, developed by the sponsor Ellipse Technologies
Inc., is used to prevent worsening of scoliosis in children
who have not responded to other treatments. The EAC
critiquing the evidence was the Newcastle upon Tyne
Hospitals NHS Foundation Trust and York Health Eco-
nomics Consortium partnership. NICE published its final
guidance on this device in June 2014.
This article provides a summary of the sponsor’s sub-
mission on the device’s clinical and cost effectiveness, and
an overview of the EAC’s outputs and subsequent devel-
opment of the NICE guidance. Full documentation of the
process, supporting evidence and the final guidance can be
found on the NICE website [2].
2 Background to the Condition and Device
Scoliosis is a structural lateral curvature of the spine, which
occurs most commonly in children and young adolescents
[3]. Scoliosis may result from other medical conditions but
more commonly has no known cause (idiopathic scoliosis)
[4]. In the majority of cases, treatment is not required and
the mild condition corrects itself as the child grows.
Children with severe and progressive disease, if left
untreated, are at risk of rapid spinal deformity progression,
cosmetic disfigurement and pulmonary insufficiency.
Untreated scoliosis can also reduce life expectancy,
because of respiratory failure. This problem is exacerbated
in children who develop scoliosis at a very young age [3].
Various options exist for children who require treatment
for scoliosis, and, as no standardized treatment guidelines
exist within England, methods differ between clinicians
and hospitals. Following diagnosis, most children will
either be observed, wear a back brace [3] or wear a cast [5].
These preventative methods aim to stop the curve from
worsening as the child grows, rather than cure the scoliosis
[6]. Surgery may be required in children for whom the
condition progresses. Spinal fusion was advocated in the
past for children with severe curves or progression despite
bracing; however, fusion can lead to arrested pulmonary
development and thoracic insufficiency syndrome (inability
of the thorax to support normal respiration and lung
growth) [3]. Growth rods were developed to limit pro-
gression of the condition, improving thoracic volume as the
child grows, whilst delaying the need for spinal fusion [7].
Growth rods are distractible spinal implants, which are
attached to the spine, using hooks and pedicle screws,
under general anaesthetic. A single rod can be attached on
one side of the curve, or, more commonly, rods are
attached to both sides of the spine (dual rods). The rods
brace the spine internally and are distracted as the child
grows, to control the progression of the spinal deformity
[8]. Conventional growth rods are lengthened every
6 months during an invasive procedure in which the sur-
geon re-opens the surgical incision site and distracts the
rods under general anaesthetic [7].
MAGEC rods are inserted in the same way as conven-
tional growth rods; however, they are distracted magneti-
cally, using an external remote controller in a noninvasive
procedure during an outpatient appointment. The sponsor
claimed that avoidance of repeated surgeries reduced the
incidence of surgical complications, reduced psychological
trauma and improved patients’ quality of life. The costs
associated with repeated surgical interventions would also
be avoided. The MAGEC system was considered by the
Medical Technologies Advisory Committee (MTAC) as an
alternative to conventional growth rods in children with
scoliosis, as defined in the scope produced by NICE. This
is described further in the following section.
3 Decision Problem (Scope)
3.1 Population
The population described in the scope was children with
scoliosis in whom a surgical distraction procedure was
indicated. This population included children who had either
idiopathic or symptomatic scoliosis and, in many cases,
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had failed on more conservative treatment methods. The
MAGEC system is contraindicated for children under the
age of 2 years.
3.2 Comparator (Current Practice)
Spine-based surgical distraction procedures with conven-
tional growth rods were specified as the comparator within
the scope. Other techniques that have been used to correct
childhood scoliosis, including the Shilla growth guidance
technique and the Luque´ trolley construct, were judged as
being out of scope for the decision problem, as these
techniques were understood not to be current standard
practice in the NHS in England. Both single and dual
conventional rod constructs were relevant.
3.3 Intervention (the MAGEC System)
The intervention outlined in the scope was the MAGEC
system, with single or dual rod constructs and an external
remote controller. Adjustments can be made with the
external remote controller to lengthen or shorten the rod, if
necessary. The growth rods are available in two diameters
(4.5 and 5.5 mm); the recommended size depends upon the
bodyweight of the child and the discretion of the surgeon.
3.4 Outcomes
Twelve outcomes were listed in the scope as being relevant
to the decision problem, and five of these were formally
addressed within the sponsor’s submission. The sponsor
considered a further seven intermediate outcome measures,
which were not identified in the scope (Table 1). The
sponsor’s included outcomes were those consistently
reported in published clinical literature, including the Cobb
angle, thoracic spine height and total spine height.
The Cobb angle is the standard method used to quantify
spinal curvature. It measures the angle between the end-
plates of the end vertebrae of the scoliotic curve measured
on a radiograph of the coronal (frontal) plane [9].
The thoracic spine region, containing 12 vertebrae (the
T1–T12 vertebrae), is the largest region of the spine. This
region of the spine protects the thoracic viscera—for
example, the heart and lungs [10]. Carrying out spinal
fusion in children with a thoracic spine height below nor-
mal height can increase the risk of restrictive lung disease
and the ‘crank shaft phenomenon’, whereby there is con-
tinued growth in the anterior of the spine when it is fused
from the posterior. Growth rods may enable children with
scoliosis to achieve an adequate thoracic spine height prior
to spinal fusion [11]. Therefore, thoracic spine height is
measured as an outcome in most growth rod studies and
was included in the sponsor’s analysis.
The total spine height (the T1–S1 vertebrae) encom-
passes the thoracic spine region and the lumbar and sacral
vertebrae lower on the spine. The reasons why it is
important for children with scoliosis to achieve adequate
total spine height include those listed for the thoracic spine
height (because of inclusion of the thoracic spine region)
and cosmetic reasons. This measure is also used in most
clinical studies of growth rods.
4 Review of Clinical and Economic Evidence
Clinical and economic evidence were submitted by the
sponsor, in line with the process set out by NICE [12]. The
sponsor submitted a de novo costing model as part of its
economic evidence. The EAC critically appraised the
submission and the costing model. Section 4.1 summarizes
the clinical evidence submitted, the EAC critique and the
EAC’s new work. Section 4.2 provides the same detail for
the economic evidence.
4.1 Clinical Effectiveness Evidence
4.1.1 Sponsor’s Review of Clinical Effectiveness Evidence
The sponsor undertook a search for published clinical
evidence relating to the decision problem, which identified
four studies suitable for inclusion [7, 13–15]. A further four
unpublished studies were identified and were included by
the sponsor [16–19]. One of these four studies has subse-
quently been published [18]. Two studies were judged as
being out of scope—one being an animal study [15] and the
other being a cost analysis [17] (which was subsequently
considered as economic evidence).
Four of the six studies were prospective case series [7,
13, 14, 18], with one being a retrospective case review [16]
and one being a retrospective case-matched series of 12
patients with MAGEC rods and 12 with conventional
growth rods [19]. Both retrospective reviews drew on
patients from several centres; details on processes such as
follow-up and measurement were not provided. The mean
follow-up period ranged from 10 months to 2.5 years, with
a weighted mean, using patient numbers as weights, of
19 months. All studies recruited patients with childhood
scoliosis, except for one study [16], which included a wider
patient group—children with any early-onset spinal
deformity.
There was some overlap of patients within the included
studies, with one study [14] including all of the patients
from another [18]; the latter is not discussed further in this
article. Twelve patients receiving a MAGEC rod in the
case-matched series [19] were included in the case review
[16]. The results of the case-matched study [19] are
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reported, despite the overlap of patients, because it is
judged important to report both arms of the only study that
included a comparator arm.
The comparator study selected by the sponsor evaluated
the clinical and radiographic complications associated with
growth rod treatment and was not an efficacy study. It
included data from 140 patients, with a mean age of
6 years (range 1.7–10 years), recorded on the multicentre
Growing Spine Study Group database. The inclusion cri-
teria were growth rod treatment for early-onset scoliosis
and a minimum of 2 years of follow-up [20].
Table 2 reports the results from the five included
MAGEC rod studies [7, 13, 14, 16, 19], as well as the
comparator conventional rod study used by the sponsor
[20].
The sponsor undertook either meta-analysis or quanti-
tative synthesis on all key outcomes, which were compared
with those of the conventional growth rod study [20] or the
conventional rod arm of the case-matched study [19]. The
reported change in the Cobb angle1 in the MAGEC rod
studies [7, 13, 14, 16] was estimated to be 27 (95 %
confidence interval [CI] 23–31), similar to the 28 (CI not
reported) reported for the comparator [20]. The change in
the total spine height1 for the MAGEC system [7, 13, 14,
16] was estimated to be 46 mm (CI 40.0–51.1)—a sub-
stantially lower value than the 77 mm (CI not reported)
achieved in the conventional rods arm of the study by
Akbarnia et al. [19]. The comparator study did not report
this outcome [20].
The change in the thoracic spine height1 of 31 mm in
the MAGEC system studies [7, 13, 14, 16] was not com-
pared with the changes reported in conventional rod stud-
ies, because of data limitations. Compared with the
findings in the conventional rod study [20], the infection
rates (15 % versus 6.4 %), numbers of surgical procedures
(6.4 versus 1.1) and numbers of device failures per patient
(0.37 versus 0.07) were lower in the MAGEC rod studies
[7, 13, 14, 16].
The sponsor concluded that the clinical evidence dem-
onstrated that MAGEC rods are equally as effective as
conventional rods and provide a reduced risk of adverse
events.
4.1.2 Critique of Clinical Effectiveness Evidence
The EAC critiqued the literature search, evidence selection
and quality assessment of the included studies completed
by the sponsor, and consulted clinical experts, identified
using NICE’s published processes, for advice on relevant
comparators and patient groups. Where possible, the EAC
repeated the sponsor’s searches and obtained a broadly
similar yield of search results. The study selection criteria
employed by the sponsor limited the intervention to the
MAGEC system and placed no constraints on outcomes,
study design, language or search dates. It was unclear how
the sponsor had selected the comparator study [20].
The EAC reviewed each paper for potential bias, limi-
tations, inconsistencies in results and uncertainty around
generalizability. Each study was graded; all were case
series, which scored 3 on the Scottish Intercollegiate
Guidelines Network (SIGN) grading [21] and ‘very low’ on
the Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) [22], thus any estimate of
Table 1 Outcomes in scope
and sponsor’s submission
NICE National Institute for
Health and Care Excellence
Outcomes to consider in scope issued by NICE Outcomes considered in sponsor’s submission
•Total numbers of surgical procedures
and anaesthetics
•Total numbers of outpatient attendances and procedures
•Recovery time
•Total length of stay
•Rate of distraction procedure success
•Infection rates and other surgical
complication rates
•Total number of imaging procedures
•Quality of life
•Device failure
•Device and radiation exposure-related
adverse events
Suggested in scope
•Total number of surgical procedures
•Total number of outpatient procedures
•Rate of distraction procedure success





•Thoracic spine height (T1–T12)
•Total spine height (T1–S1)
•Length of stay (not quantified)
•Forced volume vital capacity
•Forced expiratory volume
•Thoracic kyphosis
1 The changes in the Cobb angle, total spine height and thoracic spine
height were calculated from the random-effects model. The difference
between final follow-up results and pre-operative results were used.
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the effect is very uncertain. Meta-analysis could not miti-
gate fully against this underlying uncertainty. Case series
are prone to selection and observer bias when patients are
selected for inclusion in the study and in reporting out-
comes. The reporting of inclusion and exclusion criteria
within the included studies was generally poor, with two
studies not reporting inclusion criteria [7, 18] and only one
study reporting any exclusion criteria [14]. The sponsor
failed to provide discussion around limitations relating to
the included studies.
The technique used by the sponsor for meta-analysis
was not reported; only the results were presented. It was
thus not possible to critique the methodology and hence to
have confidence in the results. The largest weaknesses
identified following the critique were the absence of a
rationale for the choice of the comparative study, and the
lack of discussion of differences in follow-up durations
between the conventional and MAGEC rod studies and
their potential implications for comparison of outcomes.
Given these limitations within the sponsor’s submission,
the EAC undertook additional work.
The EAC undertook a literature search to identify any
MAGEC rod studies that had not been identified from the
sponsor’s search and to identify studies of conventional
growth rods to inform the comparator. A number of dat-
abases (including Medline, the Cochrane Library and
Embase) and the grey literature were searched (the strat-
egies that were adopted are available from the EAC
assessment report [2]).
The included studies of conventional rods were limited to
those that included at least 20 patients and were published
after 1 January 2008. The choice of 20 patients was informed
by a scoping search: a cut-off was required pragmatically to
enable the EAC to manage the studies within the evaluation
timescale. The 2008 filter was applied to capture studies of
current growth rod technologies and hence appropriate
comparators for MAGEC rods.
The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) diagram [23] (Fig. 1) shows
the numbers of papers that were retrieved and excluded
following dual selection by two independent reviewers,
together with the reasons for exclusion. Of the 23 included
studies, 15 [20, 24–37] were studies of conventional rods and
eight were studies of MAGEC rods [7, 13, 14, 16, 18, 19, 38,
39]. Of the eight studies of MAGEC rods, two were addi-
tional to those found from running the sponsor’s search [38,
39]; however, the sponsor advised that patients in these
studies were already included in another study [14]. The
conventional rod arm of the case-matched study [19]
included by the sponsor was also included within the evi-
dence base, totalling 16 studies. Of the 16 conventional rod
studies, 15 were retrospective case series and the remaining
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Data were extracted from the included studies, and the
weighted mean follow-up duration was calculated, using
the number of patients within each study as a weight. The
extraction was undertaken by one reviewer and checked by
a second reviewer. There were notable differences between
the conventional rod studies and the MAGEC rod studies.
The latter included a greater mean Cobb angle at baseline
(72.4 versus 65.7); a lesser mean total spine height at
baseline (258 versus 288 mm) and a younger mean age at
surgery (6.4 versus 8.0 years). These differences were
likely to influence the potential changes in each outcome
over time. For example, a greater height at baseline may
limit the potential for growth during follow-up periods;
similarly, a less severe Cobb angle may limit the potential
improvement in that outcome. The mean duration of fol-
low-up in the conventional rod studies was 4.3 years (range
2.5–6.6 years). This was materially longer than the follow-
up in any of the MAGEC system studies (range 10 months
to 2.5 years). The number of distractions is a function of
time, and these are related to other outcomes of interest,
including the change in the Cobb angle, the change in spine
height and the change in infection rates. Hence the dif-
ference in the follow-up durations was a major source of
confounding and limited the ability to use the evidence to
inform recommendations.
Meta-analyses were undertaken by the EAC for the
MAGEC rod and conventional rod studies, following data
extraction into a predefined template. The data items that
were required included changes in mean differences in the
Cobb angle and spine height, and a measure of variance.
Not all studies provided usable data. Given the variation in
the duration of follow-up between the two sets of studies,
the studies were grouped into those with less than, or
greater than, 38 months of follow-up. Those conventional
rod studies with a follow-up period of less than 38 months
were considered to be more comparable to the MAGEC rod
studies. The few (n = 3 to n = 8) studies of conventional
rods that provided sufficient statistical data to enable them
to be included in the longer-term follow-up analyses is an
indication of how poor the reporting of many of these
studies was. Variance, ranges and CIs were particularly
poorly reported. The MAGEC rod studies reported results
better than the majority of the conventional rod studies.
This variation in reporting could be explained in part by the
prospective nature of four of the six MAGEC rod studies
[7, 13, 14, 18], compared with the retrospective nature of
all but one [28] of the conventional rod studies.
The included studies and their results are shown in
Table 3. Fixed- and random-effects models were fitted.
Heterogeneity was assessed by using the I2 statistic, which
measures the percentage of variation across studies that is
due to heterogeneity rather than sampling error. Bench-
marks were suggested for I2: values of the order of 25 %
were considered low, 50 % moderate and 75 % high [40].
Where studies were heterogeneous, the random-effects
model was more appropriate because (unlike the fixed-
effects model) it incorporates the heterogeneity among
studies. The results for meta-analysis with low heteroge-
neity scores tend to be similar for the fixed- and random-
effects models.
The mean differences in the Cobb angle between base-
line and follow-up were 27 for the MAGEC rod group and
32 for the longer follow-up conventional rod group (CI
reported in Table 3). However because of the differences in
follow-up periods, the meta-analysis results for these two
groups were unlikely to be comparable. Only one study had
sufficient data to be included in the shorter follow-up group
[37], and there was considerable variation between this and
the conventional growth rod studies with longer follow-up.
For the total spine height, the estimated mean difference
between baseline and follow-up was 4.55 cm with
MAGEC rods and 10.76 cm with conventional rods (in the
shorter follow-up group). The very high heterogeneity
between the conventional rod studies greatly limits the
confidence of those results. Pfandlsteiner et al. [29]
reported the highest value for changes in the total spine
height of all of the studies. The patients in their study
tended to be older at the time of surgery than those in the
Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) flow diagram for External Assessment Centre
(EAC) clinical evidence review
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other studies. If that study is excluded, the results for this
group are based on the study by Wang et al. [37] only, for
which a mean change in the total spine height of 7.96 cm
was reported. The average number of infection episodes
per patient with MAGEC rods was 0.03–0.04. For the
shorter follow-up conventional rod group, the estimated
average number of infection episodes per patient was about
0.03, and heterogeneity was quite high. Only two studies
had enough data to be included in the meta-analysis. Wang
et al. [37] only reported on deep wounds and not both deep
and superficial wounds, as was the case for the rest of the
studies. If that study is excluded, the results for this group
are based on the study by Zhao et al. [33], who reported an
average number of infection episodes per patient of 0.12.
The average number of infection episodes per patient in the
longer follow-up group was estimated to be around
0.14–0.15.
Quantitative analysis was carried out around device
failure (limited to rod breakage, rather than either failure to
distract or screw failure), the rate of surgical procedures
and the rate of distraction. The mean number of distrac-
tions per year was greater for the MAGEC rod studies (4.5)
than for all conventional rod studies (1.1). The mean
number of surgeries per patient per year was smaller in the
MAGEC studies (0.9) than in the conventional rod studies
(1.5 for shorter follow-up and 1.1 for longer follow-up).
The mean rates of device failure per child were lower in the
MAGEC group than in either conventional growth rod
group (MAGEC studies 6 %, shorter follow-up conven-
tional rod studies 13 %, longer follow-up conventional rod
studies 31 %); however, the annualized rates were similar
at around 4.5 % in the MAGEC rod studies and in the
shorter follow-up conventional rod studies, with the longer
follow-up studies having an annualized rate of 7.2 %.
Information on the impact of the procedure on quality of
life was reported in only one study [7]. No evidence was
reported on ability to conduct daily activities, school
attendance or psychological trauma. The sponsor claimed
that use of the MAGEC system would improve these
aspects, compared with conventional growth rods. Clinical
experts advised the EAC and MTAC of the psychological
trauma that some children with conventional growth rods
experience as a result of the need for repeated surgeries. In
some instances, children have developed ‘hospital phobia’
and refused any further distractions. As the use of the
MAGEC system overcomes the need for repeated surgery,
limiting benefit to the clinical endpoints may understate the
value that patients place on the improvement they
experience.
The results from the meta-analysis were subject to
limitations arising from the high heterogeneity existing
across the conventional rod studies; the confounding factor
of differences in the baseline characteristics of patients in
the MAGEC and conventional rod studies (relating to the
total spine height, age and Cobb angle), fundamental dif-
ferences in the study designs and the substantially shorter
follow-up duration reported in the MAGEC rod studies.
The EAC judged that there was neither the quality nor the
quantity of evidence to draw firm conclusions around the
clinical efficacy of MAGEC rods compared with conven-
tional rods and, as such, MAGEC rod studies with longer
follow-up durations are required. From a patient
Table 3 Results of the External Assessment Centre (EAC) meta-analysis
Parameter Number of studies included Heterogeneity
(I2 statistic)
Mean (95 % CI)
Fixed-effects model Random-effects model
Cobb angle
MAGEC rods 4 [7, 13, 14, 16] 44.89 27.16 (24.41–29.92) 27.17 (23.12–31.22)
Conventional rods
Shorter follow-up 1 [37] NA (1 study) 37.03 (27.26–46.80) –
Longer follow-up 4 [25, 27, 30, 32] 34.83 32.14 (28.91–35.36) 32.90 (28.61–37.18)
Change in total spine height
MAGEC rods 4 [7, 13, 14, 16] 0 4.55 cm (3.98–5.11) 4.55 cm (3.98–5.11)
Conventional rods
Shorter follow-up 2 [29, 37] 92.33 12.29 cm (11.16–13.43) 10.76 cm (5.53–15.98)
Longer follow-up 3 [25, 27, 30] 96.5 4.25 cm (3.77–4.72) 6.43 cm (2.70–10.15)
Infection rates (per patient)
MAGEC rods 4 [7, 13, 14, 16] 61.68 0.03 (0.00–0.08) 0.04 (0.00–0.15)
Conventional rods
Shorter follow-up 2 [33, 37] 83.65 0.03 (0.00–0.08) 0.03 (0.00–0.25)
Longer follow-up 8 [20, 24, 25, 27, 28, 31, 32, 35] 57.33 0.14 (0.11–0.16) 0.15 (0.11–0.20)
CI confidence interval, NA not applicable
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perspective, the absolute number of surgeries is the key
driver. It was apparent from the clinical evidence that this
number was reduced with MAGEC rods compared with
conventional rods.
4.2 Economic Evidence
4.2.1 Sponsor’s Economic Submission
The sponsor undertook a limited search for economic
evidence, which was based upon the strategy reported by
Richards and Nnadi in their cost study [17]. No other
economic studies were identified, hence that study [17] was
the only economic study to be included. Richards and
Nnadi collected data from 14 children undergoing growth
rod surgery for scoliosis. The included patients either
underwent primary surgery (MAGEC insertion) or con-
version surgery (replacement of conventional rods with
MAGEC rods). A unit cost analysis was undertaken to
compare the costs of conventional growth rod treatment
(n = 8 children) and MAGEC rod treatment (n = 14
children). The authors used the data that were collected and
the costs that were calculated to forecast cost savings over
a 10-year time horizon [17].
A de novo temporal cost minimization model was sub-
mitted by the sponsor and compared the MAGEC system
and conventional growth rods over a 6-year time horizon
from a NHS and Personal Social Services perspective, with
the year of valuation being 2012. The model was created in
Statistical Analysis Software, and the results were copied
into Microsoft Excel for submission. The structure of the
model was identical for both the treatment and the com-
parator. In month 0, the cost of insertion of the rods, plus
the cost of complete device failure multiplied by the inci-
dence of this failure, were included. In subsequent months,
the cost of each lengthening was added, and the total
cumulative cost after 6 years was calculated for both the
MAGEC and conventional rod arms of the model.
The costs of rod insertion, rod lengthening and device
failure for MAGEC and conventional rods were obtained
from Richards and Nnadi [17]. Other model inputs were the
frequency of rod lengthening and the rate of device failure.
Within the sponsor’s model, the cost of distraction of
MAGEC rods was applied every 3 months, and that of
conventional rod lengthening was applied every 6 months.
In the base case, a device failure rate of 0 % was assumed.
The results were reported as the month in which
breakeven occurred between the devices, absolute costs
(analysed by cost category) and cost differences at 6 years.
The base case results from the model showed that MAGEC
rods generated cost savings of £9,946 per patient after
6 years, compared with conventional rods. At 6 years, the
cumulative per-patient cost of MAGEC rods was £36,094
versus £46,040 for conventional rods. Breakeven between
the two types of rod occurred in the 39th month after
insertion.
The only sensitivity analysis that was conducted varied
the rate of device failure (from 0 % used in the base case).
First, an 8.8 % failure rate was considered for both arms of
the model, taken from the mean device failure for MAGEC
rods in the clinical evidence [7, 13, 14, 16, 19]. Second, a
device failure rate of 17.2 % (the highest rate for MAGEC
rods in the clinical evidence) was used [16]. Finally, an
8.8 % failure rate in month 0 was considered for both arms
of the model, and an additional device failure rate of 1.76
per patient was included at month 13 for conventional rods.
The additional device failure at month 13 was misquoted
from Yang et al. [41].
The results of the sponsor’s univariate sensitivity ana-
lysis on the rate of device failure found that the MAGEC
system was always cost saving after 6 years. These savings
ranged from £8,109 (breakeven at month 45) where device
failure occurred 17.2 % of the time in both arms of the
model, and £12,984 (breakeven at month 28) where addi-
tional device failure, specific to conventional rods, occur-
red only at month 13. The results of the sponsor’s de novo
model led the sponsor to conclude that even with the most
conservative assumptions, the MAGEC system is cost
saving, compared with conventional growth rods, and cost
savings are usually realised during the third year following
insertion.
4.2.2 Critique of Economic Evidence
A critique of the sponsor’s submission was undertaken,
which included the literature search for economic evi-
dence, selection of the included studies, the included evi-
dence and the de novo economic model. The EAC
attempted to replicate the sponsor’s literature search of
PubMed for published economic evidence, using the lim-
ited description provided, and also undertook its own
search in specialist databases indexing economic research
(the databases that were searched and the strategies that
were used are available from the EAC assessment report
[2]). No economic studies additional to the one included by
the sponsor [17] were identified.
Given that the economic evidence base consisted of only
one study, it was appropriate for the sponsor to build a
de novo economic model. The EAC judged that the
sponsor’s de novo costing model captured the key cost
considerations relating to the decision problem. There
were, however, limitations relating to the model structure
and inputs, which the EAC explored.
The modelled cost inputs were taken from the study by
Richards and Nnadi [17], which included 14 patients. The
EAC acknowledged that there was a lack of published
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economic evidence available. It sought to verify all inputs
used in the model, using data from other sources and expert
advice. Other clinical inputs were also validated where
possible. After consideration of the components of the
model cost inputs, the EAC judged that the sponsor had
overestimated the cost of MAGEC rod insertion, MAGEC
rod lengthening and conventional rod insertion, and had
underestimated the cost of conventional growth rod
lengthening and the cost of device failure for both devices.
The EAC contacted clinical experts for advice on the
suitability of the structural assumptions that had been made
by the sponsor. The key assumption of the sponsor’s
de novo model was that the clinical efficacy of all out-
comes was equivalent between MAGEC and conventional
rods. Given the lack of good-quality clinical evidence, it
was not possible to prove or disprove this assumption.
Four further structural assumptions were made. First, no
adverse events other than device failure were incorporated
into the model; however, the EAC deemed that infection
rates were well reported within the clinical evidence and
should be included within the model. Second, device fail-
ure occurred immediately or not at all (except in the final
sensitivity analysis in the conventional growth rod arm of
the model). Clinical experts advised that device failure
occurring only in the same month as rod placement is
unlikely. Third, all parameters in the model were identical
for both single and dual rods for both the treatment and the
comparator, despite large cost variations between single
and dual rods. Finally, no discounting was applied within
the model. The NICE methods guide states that ‘‘A dis-
count rate of 3.5 % (per year), as recommended by HM
Treasury, is used to reflect the time value of costs and
benefits’’ [42].
Because of these structural limitations, the EAC repli-
cated the sponsor’s model in Microsoft Excel (making it
fully executable) and made four adaptations to the model
structure. First, surgical site infections, as reported in the
clinical evidence, were included within the model. For
conventional growth rods, a monthly infection rate was
applied, as these patients undergo both initial insertion
surgery and ongoing surgery for distractions. The monthly
rate was calculated from the nine studies that reported
infection rates in patients with conventional growth rod
[20, 24, 25, 27, 28, 31–33, 37]. For the MAGEC system,
infections were assumed to occur in month 0—the same
month as the initial rod insertion—with the infection rate
being calculated from four studies reporting this informa-
tion [7, 13, 14, 16].
Second, the EAC calculated and applied a monthly rate
of device failure over the 6-year time horizon of the model
for both the MAGEC system and conventional rods. This
was consistent with the advice received from clinical
experts, who, on the whole, said that rod breakage could
occur at any time. The monthly rate of complete rod
breakage was established using the clinical evidence for
both the MAGEC system [7, 13, 14, 16] and conventional
growth rods [20, 24, 25, 27–33, 37].
Third, the EAC weighted the cost of the device in both
arms, according to the proportion of patients receiving
single and dual rods within the clinical evidence (65 %
dual MAGEC rods and 64 % dual conventional rods).
Finally, the EAC discounted costs at a rate of 3.5 % per
year, as recommended by HM Treasury [42]. The model
input parameters were also updated by the EAC, following
validation by clinical experts and against other sources
where possible.
Following the amendments made by the EAC to the
model structure and inputs, the EAC found that MAGEC
rods generated cost savings of £12,077 per person over the
6-year time horizon. The cumulative discounted cost over
6 years was £38,242 for MAGEC rods and £50,319 for
conventional growth rods, with breakeven at month 35.
Extensive deterministic sensitivity analysis was under-
taken around the model inputs. Each model input was
varied within a range deemed plausible following consid-
eration of the published evidence and advice from clinical
experts. One-way sensitivity analysis showed that the
model was robust to changes in most parameters, but it
highlighted that the cost and the frequency of distractions
of conventional growth rods were the key drivers of the
model. This was confirmed by the two-way sensitivity
analysis. MAGEC rods would be the more expensive
technology if conventional growth rods are distracted less
frequently than every 10.2 months if and the majority of
distractions are undertaken as outpatient procedures with
no complications. Advice from clinical experts suggested
that this is unlikely; hence MAGEC rods are likely to be
cost saving, compared with conventional rods, when used
in the context of the NHS.
5 NICE Guidance
5.1 Provisional Recommendations
The evidence submitted by the sponsor and the EAC’s
critique of this evidence was presented to MTAC, who
provided draft recommendations relating to MAGEC rods
following their meeting in December 2013. These were as
follows:
‘‘1.1 The case for adopting the MAGEC system for
spinal lengthening in children with scoliosis is sup-
ported by the evidence. Using the MAGEC system
would avoid repeated surgical procedures for growth
rod lengthening. This could reduce complications and
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have other physical and psychological benefits for
affected children and their families.’’
‘‘1.2 The MAGEC system is indicated for use in
children with scoliosis, usually aged between 2 and
11 years, who need surgery to correct their spinal
curvature, for example when conservative methods
such as bracing or casting have failed.’’
‘‘1.3 Findings from cost modelling estimate that
using the MAGEC system is cost saving compared
with conventional growth rods from about 3 years
after the initial insertion procedure. The estimated
cost saving per patient after 6 years is around
£12,077. The cost savings remained robust in sensi-
tivity analyses’’ [2].
5.2 Consultation Response
During the consultation, NICE received 23 comments from
eight consultees; consequently, the recommendations were
amended to clarify the age group for which the MAGEC
system is indicated. This change was also incorporated as
part of the technology description, together with an
explanation of when the MAGEC system rods should be
removed.
A description of the potential increase in cost savings
generated by use of the MAGEC system instead of conven-
tional growth rods, through avoidance of spinal cord moni-
toring, was added to the recommendations. The system
impact section of the guidance was expanded to explain that
spinal cord monitoring is not needed when lengthening
MAGEC rods, but it may be used in conventional rod
lengthening. A paragraph was added to the cost evidence and
considerations to include findings from revised cost model-
ling by the EAC to calculate the potential cost savings that
would be achieved if spinal cord monitoring is not used
during MAGEC lengthening procedures.
Other sections of the guidance were changed to reflect
the uncertainty in the proportion of children not requiring
interventional treatment for scoliosis, and to provide a
more accurate estimate of the number of children who may
be eligible for treatment with the MAGEC system in
England each year. Minor revisions were made to other
sections to improve clarity.
6 Key Challenges and Learning Points
The key challenge faced by both the sponsor and the EAC
was the lack of robust comparative studies providing evi-
dence on the MAGEC system versus conventional rods.
The sponsor’s clinical evidence was limited to one
comparative study [19] and five case series [7, 13, 14, 16,
18], which had small sample sizes, often included hetero-
geneous patients and were conducted by different surgeons,
with no consistent operating procedures. These were gra-
ded as very low quality evidence, with any estimate of the
effect size being uncertain. A meta-analysis of these studies
was conducted, which was compared with a large con-
ventional growth rod study [20].
The EAC attempted to overcome the limitation in
comparative studies by conducting a literature review to
identify relevant conventional rod studies and by under-
taking meta-analysis on outcomes reported in these studies.
Despite this, major limitations existed because of high
study heterogeneity (meaning some meta-analysis results
could not be used), differences in follow-up durations and
variations in the baseline characteristics of the participants.
For example, the mean age at surgery for patients who
were included in the conventional growth rod studies was
6.4 years, compared with 8.0 years in the MAGEC rod
studies. Therefore, the patients in the MAGEC system
studies may have had less potential for growth. Statistical
techniques cannot readily adjust for such confounding
factors.
The sponsor’s economic analysis was based upon one
single-site cost comparison study [17]; uncertainties exis-
ted around the external validity of the modelled cost data.
Further, the sponsor’s model was not fully executable,
meaning that the EAC had to replicate the model in Excel
prior to developing a range of scenarios and sensitivity
analysis. In order to fully validate the model, the sources of
all assumptions needed to be made clear by the sponsor.
Transparent communication between the EAC and the
sponsor facilitated this. Advice from clinical experts and
use of national cost data enhanced the external validity of
the model produced by the EAC.
7 Conclusion
The MTEP evaluation process was followed for the
MAGEC system. This included a submission of clinical
and economic evidence by the sponsor, critical appraisal of
this evidence by the EAC, additional work to address
remaining uncertainties, drafting of recommendations by
MTAC, and a subsequent consultation. Following this
process, MTAC judged that the evidence demonstrated
sufficient potential benefits of the MAGEC system to
patients and the NHS to allow positive recommendations to
be made for the device.
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